Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

Decisions 10th April 2018

Checked: not set yet by Next Review: not set yet

At the meeting that took place on 10th April, the following decisions were agreed:

 

New Drug Requests

 

Approved

Fobumix Easyhaler® (budesonide/formoterol)

  • Approved for inclusion onto the formulary for asthma and COPD. DuoResp Spiromax® to be made non-formulary

 

Not Approved

Apixaban

  • Not approved for inclusion onto the formulary for patients undergoing mitral valve repairs and tissue mitral valve replacements

 

Shared Care Protocols/TLS Change in Status

Dymista® Nasal Spray  (TLS amber to green)

  • The extra evidence provided was discussed and it was concluded it did not demonstrate dymista nasal spray to be more effective than other sprays on the formulary or reduce referrals. To remain TLS amber.

Quinagolide (TLS red to amber)

  • Change of TLS from red to amber 3 months agreed

Testosterone undecanoate (Nebido®) and testosterone decanoate, isocaproate, phenylpropionate and propionate (Sustanon®)

  • New SCPs brought to meeting, however clarification of time frame for measuring testosterone levels required before can be agreed

Azathioprine

  • Updated SCP and advise sheet approved

Hydroxychloroquine

  • Updated SCP and advise sheet approved

Riluzole

  • Updated SCP approved

Modafinil (TLS red to amber)

  • Change of TLS from red to amber 3 months, SCP agreed

Levodopa,carbidopa and entacapone combined tablet

  • Updated SCP approved

Entacapone

  • Updated SCP approved

 

Other

Fiasp®

  • The JFG agreed the use of Fiasp® for patients requiring multiple injections where post-prandial hyperglycaemia is a particular problem.